ArticleComputational and structural biotechnology journal2025
BCMA: An integrative and versatile database for multi-scale and multi-omics molecular atlas of breast cancer.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is one of the most common cancer types among women worldwide. Understanding the complex molecular and cellular characteristics of BC is crucial for advancing precision treatment. To enable more reliable and reproducible biological discoveries, it is critical to collect molecular data from diverse BC cohorts and establish an integrative, versatile analysis platform. Here, we present BCMA (Breast Cancer Molecular Atlas, http://lifeome.net/database/bcma/), a multi-scale, multi-omics BC database that encompasses 6 bulk multi-omics datasets and 9 single-cell transcriptomics datasets, collectively covering 5424 cases and 236,363 cells. The BCMA systemically characterizes the molecular features of BC, including gene mutations, copy number alterations, RNA expression, miRNA expression, DNA methylation, as well as clinical phenotypes and cell heterogeneity. Meanwhile, a user-friendly interface for gene-centered search is provided, achieving the clinical information statistics, genomic events analysis, differential multi-omics feature identification, functional enrichment analysis, survival analysis, co-expression analysis, as well as single-cell gene expression profiling and cell type annotation. This platform holds great potential to enhance the understanding of molecular characteristics underlying BC and to facilitate the identification of disease-associated biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.